Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Solidion Technology Stock Is Trending — Here′s What′s Behind STI′s Near 360% Surge (Benzinga) +++ SOLIDION Aktie -4,92%

COSMOS HEALTH Aktie

 >COSMOS HEALTH Aktienkurs 
0.245 EUR    +4.2%    (TradegateBSX)
Ask: 0.246 EUR / 8124 Stück
Bid: 0.24 EUR / 3331 Stück
Tagesumsatz: 11700 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>COSMOS HEALTH Performance
1 Woche: +3,1%
1 Monat: -21,9%
3 Monate: -28,9%
6 Monate: -47,6%
1 Jahr: -40,8%
laufendes Jahr: -44,9%
>COSMOS HEALTH Aktie
Name:  COSMOS HEALTH DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US2214133058 / A3DZZN
Symbol/ Ticker:  V67A (Frankfurt) / COSM (NASDAQ)
Kürzel:  FRA:V67A, ETR:V67A, V67A:GR, NASDAQ:COSM
Index:  -
Webseite:  https://www.cosmoshealthi..
Profil:  Cosmos Health Inc. is a diversified, vertically integrated global healthcare group specializing in pharmaceuticals, nutraceuticals, healthcare services, and digital assets. The company engages in the importation, exportation, distribution, and sale o..
>Volltext..
Marktkapitalisierung:  13.02 Mio. EUR
Unternehmenswert:  27.13 Mio. EUR
Umsatz:  59.76 Mio. EUR
EBITDA:  -14.19 Mio. EUR
Nettogewinn:  -18.17 Mio. EUR
Gewinn je Aktie:  -0.56 EUR
Schulden:  15.89 Mio. EUR
Liquide Mittel:  1.86 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  0.06
Umsatzwachstum:  21.49%
Gewinnwachstum:  -30.75%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  COSMOS HEALTH
Letzte Datenerhebung:  05.06.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 59.96 Mio. St.
Frei handelbar: 55.41%
Rückkaufquote: -47.87%
Mitarbeiter: 163
Umsatz/Mitarb.: 0.34 Mio. EUR
Analysten:
Analystenrating: No rating
Kursziel: 1614.56%
Bewertung:
KGV: -
KGV lG: 26.17
KUV: 0.19
KBV: 0.54
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 8.39%
Gewinnmarge: -30.41%
Operative Marge: -25.75%
Managementeffizenz:
Gesamtkaprendite: -35.35%
Eigenkaprendite: -92.33%
>Peer Group
Handel, Apotheken, Drogerien & Pharmavertrieb
 
04.06.26 - 22:00
 Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz (GlobeNewswire EN)
 
Sky Premium Life is now available for shipment across all 27 European Union Member States through Skroutz....
04.06.26 - 15:27
 Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value (GlobeNewswire EN)
 
Cosmos Health identifies approximately $20 million in non-core assets available for monetization to accelerate growth and unlock shareholder value....
01.06.26 - 14:27
 Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657 (GlobeNewswire EN)
 
Cosmos Health enters the animal health market, extending the C-Scrub brand into the veterinary space following successful European standard testing....
21.05.26 - 20:31
 Cosmos Health Inc.: Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants (Accesswire)
 
No dilution to existing shareholdersReduction in total outstanding warrant overhangSimplifies capital structure CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. ("Cosmos Health" or......
21.05.26 - 15:30
 Cosmos Health Inc.: Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders′ Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway (Accesswire)
 
Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segmentsTotal liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in c......
14.05.26 - 15:06
 Cosmos Health Inc.: Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB&pri (Accesswire)
 
Advisory Agreement Secured: To advance the Company's EIB-backed R&D financing program€25 million potential financing opportunity: Up to 50% of the Company's €50 million planned R&D programInstituti......
12.05.26 - 16:30
 Cosmos Health Inc.: Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / May 12, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced tha......
11.05.26 - 20:30
 Cosmos Health Inc.: Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it ......
08.05.26 - 17:31
 Cosmos Health Inc.: Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed (Accesswire)
 
2026 revenue forecast raised: Zacks increases 2026 revenue estimate to $103.2 million, up from $98.6 million in its prior January 2026 reportEPS outlook upgraded: Zacks now expects Cosmos Health to......
06.05.26 - 16:42
 Cosmos Health Inc: Cosmos Health Introduces Fort18 in the United States - A Men′s Sexual Stamina Supplement Expanding the 18 Series into Men′s Wellness (Accesswire)
 
Science-based men's wellness: Fort18 is formulated with a proprietary five-ingredient botanical blend intended to support men's sexual staminaLarge and growing market: The U.S. sexual health supple......
30.04.26 - 19:06
 Cosmos Health Inc.: Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced t......
21.04.26 - 19:06
 Cosmos Health Inc.: Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 C (Accesswire)
 
Science-first nutraceutical platform: Every "18" product must clear three criteria before reaching market - a patented ingredient, peer-reviewed clinical evidence, and the exact dose studied in cli......
20.04.26 - 17:06
 Cosmos Health Inc: Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Acro (Accesswire)
 
Phase 1 complete: product development, packaging, and initial commercial setup finalized ahead of scheduleProduction commencing April 2026: GMP-certified, FDA-registered, UL-audited U.S. manufactur......
17.04.26 - 20:06
 Cosmos Health Inc.: Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health (Accesswire)
 
Clinically studied curcumin formulation demonstrating significantly enhanced absorption versus standard 95% curcuminoid extracts.Derived predominantly from turmeric (~98.5%), maintaining a composit......
16.04.26 - 21:30
 Cosmos Health Inc.: Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30% (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / April 16, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced t......
15.04.26 - 15:31
 Cosmos Health Inc.: Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Recor (Accesswire)
 
Scaled contract manufacturing division, securing long-term agreements for over 12 million unitsExpanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase ord......
13.04.26 - 19:06
 Cosmos Health Inc.: Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / April 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced t......
10.04.26 - 16:00
 Cosmos Health sees strong growth, unaffected by Middle East tensions (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.04.26 - 15:54
 Cosmos Health Inc.: Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months (Accesswire)
 
CHICAGO, IL / ACCESS Newswire / April 10, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed t......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Dem Morgenrot und dem Frauenrat ist nicht zu trauen. - Sprichwort Frankreich
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!